1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Tris wins FDA OK for Karbinal in allergic rhinitis

 
• By Donna Young

Tris Pharma won the US FDA's approval to market Karbinal ER (carbinoxamine maleate) as the first sustained-release histamine receptor blocking agent indicated to treat seasonal and perennial allergic rhinitis in children 2 years or up.

Tris Pharma won the US FDA's approval to market Karbinal ER (carbinoxamine maleate) as the first sustained-release histamine receptor blocking agent indicated to treat seasonal and perennial allergic rhinitis in children 2 years or up.

The drug also is indicated for vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, amelioration of the severity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

More from Therapeutic Category

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.